Gout Disease Treatment Market Synopsis:
Gout Disease Treatment Market Size Was Valued at USD 2.58 Billion in 2023, and is Projected to Reach USD 5.34 Billion by 2032, Growing at a CAGR of 8.4 % From 2024-2032.
Gout disease treatment market includes all the drugs and therapeutic products that are used to cure this disease which is an inflammatory form of arthritis developing acute pain, redness, and swelling in the joint. This market consists of several treatments like NSAIDs, corticosteroids, ULTs that target to minimize levels of uric acid in the bloodstream, prevent acute gout episodes and efficiently manage chronic gout. What has become predominant: the need for the development of new solutions for treating gout associated with such factors as obesity, diet, and the aging population, makes the market an essential segment of the health care industry.
Trends: The global gout disease treatment market has been growing over the last few years due to the increasing patients’ awareness of the disease and the existent therapy. That gout has been on the rise and this is especially so among the elderly and patients with conditions like hypertension and diabetes mean that the healthcare cost has gone up and people are demanding better solutions to this condition. The market is defined by the types of therapy, conventional non-selective NSAIDs, and new biological that demonstrate more personalized approaches to the disease. Furthermore, the medical field has experience significant growth in terms of treatment as they have introduced new therapies sparking the use of Janus kinase (JAK) inhibitors and interleukin inhibitors which seem to work effectively in controlling gout flares and offering long term effective solution.
Besides, market factors such as increased incidence of lifestyle diseases and shift in dietary habits that cause elevated levels of uric acid. The advancement of telemedicine and digital health has also enhanced the accessibility of healthcare, by providing appropriate diagnosis of the gout condition. In respect with changes in the structures of healthcare systems, producers of medications are paying attention to maintaining more patient-centered approach, increasing compliance with medications, and raising the general level of patients’ satisfaction for those experiencing gout.
Gout Disease Treatment Market Trend Analysis:
Growing Focus on Preventive Measures
-
A tremendous consideration in the global gout disease treatment market is that there is a growing focus on the prevention strategies with necessary healthy modifications as a way of mitigating the gout attack risks. More healthcare professionals are adopting dietary modifications, weight loss and exercise as keyetical aspects of treating gout. This change in management style is to ensure the patient is kept informed of ways and means of prevention, manage and prevent acute attack. In addition, the current educational programs and awareness raising campaigns for patients are being developed for improving understanding of the necessity of monitoring the level of uric acid and the relation of their lifestyle to disease. With such growth of the patient involvement in their treatment process and the consequences thereof, the popularity of adjunct therapies and support services is also likely to go up, and so are the opportunities for both healthcare providers as well as members of this market.
Expansion into Emerging Markets
-
The market for the gout disease treatment is in its growth stage and has a great potential especially in the developing world where incidences of gout are escalating due to change in human lifestyle and increased urbanization. For a long time now, Asia-Pacific, Latin American, and some Middle East countries have reported a high incidence of gout resulting from new dietary habits and desk-bound lifestyles. There is therefore an opportunity for pharmaceutical companies to diversify their products and come up with networks in those regions. Moreover, growing disposable income levels and better healthcare facilities in these markets create a favorable setting for new treatment of gout in the markets. By so doing, firms can thus capture the market and increase the market size for gout treatment in those regions of the world due to cultural and economic factors.
Gout Disease Treatment Market Segment Analysis:
Gout Disease Treatment Market is Segmented on the basis of type, Disease Condition, Distribution channel, and Region
By Type, NSAIDs segment is expected to dominate the market during the forecast period
-
Highly effective in addressing pain and inflammation common to gout flares, the NSAIDs segment of the market is expected to dominate the gout disease treatment market throughout the given forecast period. First line drugs include non-steroid- dal anti-inflammatory drugs-NSAIDs like indomethacin, naproxen, and ibuprofen. Due to the ongoing focus of healthcare providers on achieving rapid patient relief of gout flare pain, the category is expected to maintain its dependence on NSAIDs. Also, the rising patient and medical practitioners’ knowledge that gout management is feasible using NSAIDs is likely to enhance the product adoption while solidifying its market position as the leading treatment method.
By Disease Condition, acute segment expected to held the largest share
-
The acute gout market is expected to capture the largest market share of this gout disease treatment market since the disease commonly experiences sudden and severe attacks. The acute gout attack symptoms are severe pain, swelling, and discomfort measures that force patients to look for therapy. Therefore, therapies designed to alleviate acute manifestations are often used to control inflammation and pain with NSAIDs, corticosteroids, and colchicine. Due to higher prevalence of acute gout attacks and rise in diagnosis, the market should continue to witness high demand for treatments on this segment while maintaining its overall domination over the one.
Gout Disease Treatment Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
-
North America accounted for the largest revenue market of 47.81% in the overall gout therapeutics market in 2022 because of the existence of leading gout therapeutics companies, high cases of gout disease, and increased gout awareness that is associated with high diagnostic and treatment demand in the U.S. The strong access and healthcare indexes in the reported area, combined with the expected new-releases of drugs in the subsequent years, is expected to strengthen its market position in the commending years with the U.S leading the ratio followed by Canada. Other similar structures such as the Gout & Uric Acid Education Society embarks on awareness creation, having recently launched a campaign known as the National Gout Awareness Day and support from well-established celebrities like football players Emmitt Smith who partnered with Takeda pharmaceuticals to launch the “Champion for Gout Awareness” contributes immensely in making people aware of gouty arthritis. Such awareness leads many patients to get tested, helping markets gain more clientele as many out there do not know the status of their health. However, it is expected that the Asia Pacific shall be the fastest-growing segment in the whole market on account of the increasing number of gout patients in the region and increasing attraction of major players in the pharma industry, where segment growth in the coming years is expected to be quite tempting.
Active Key Players in the Gout Disease Treatment Market:
-
Amgen (USA)
- AstraZeneca (UK)
- Bayer AG (Germany)
- Bristol-Myers Squibb (USA)
- Eli Lilly and Company (USA)
- GSK (UK)
- Horizon Therapeutics (USA)
- Merck & Co. (USA)
- Mylan N.V. (USA)
- Novartis (Switzerland)
- Pfizer (USA)
- Sanofi (France)
- Takeda Pharmaceutical Company (Japan)
- Teva Pharmaceutical Industries (Israel)
- UCB (Belgium)
- Other Active Players
|
Global Gout Disease Treatment Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 2.58 Billion |
|
Forecast Period 2024-32 CAGR: |
8.4% |
Market Size in 2032: |
USD 5.34 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Disease Condition |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Gout Disease Treatment Market by Type
4.1 Gout Disease Treatment Market Snapshot and Growth Engine
4.2 Gout Disease Treatment Market Overview
4.3 NSAIDs
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 NSAIDs: Geographic Segmentation Analysis
4.4 Corticosteroids
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Corticosteroids: Geographic Segmentation Analysis
4.5 Colchicine
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Colchicine: Geographic Segmentation Analysis
Chapter 5: Gout Disease Treatment Market by Disease Condition
5.1 Gout Disease Treatment Market Snapshot and Growth Engine
5.2 Gout Disease Treatment Market Overview
5.3 Acute
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Acute: Geographic Segmentation Analysis
5.4 Chronic
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Chronic: Geographic Segmentation Analysis
Chapter 6: Gout Disease Treatment Market by Distribution Channel
6.1 Gout Disease Treatment Market Snapshot and Growth Engine
6.2 Gout Disease Treatment Market Overview
6.3 Hospital Pharmacies
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospital Pharmacies: Geographic Segmentation Analysis
6.4 Retail Pharmacies and Online Pharmacies
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Retail Pharmacies and Online Pharmacies: Geographic Segmentation Analysis
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Gout Disease Treatment Market Share by Manufacturer (2023)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 AMGEN (USA)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 ASTRAZENECA (UK)
7.4 BAYER AG (GERMANY)
7.5 BRISTOL-MYERS SQUIBB (USA)
7.6 ELI LILLY AND COMPANY (USA)
7.7 GSK (UK)
7.8 HORIZON THERAPEUTICS (USA)
7.9 MERCK & CO. (USA)
7.10 MYLAN N.V. (USA)
7.11 NOVARTIS (SWITZERLAND)
7.12 PFIZER (USA)
7.13 SANOFI (FRANCE)
7.14 TAKEDA PHARMACEUTICAL COMPANY (JAPAN)
7.15 TEVA PHARMACEUTICAL INDUSTRIES (ISRAEL)
7.16 UCB (BELGIUM)
7.17 OTHER ACTIVE PLAYERS
Chapter 8: Global Gout Disease Treatment Market By Region
8.1 Overview
8.2. North America Gout Disease Treatment Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By Type
8.2.4.1 NSAIDs
8.2.4.2 Corticosteroids
8.2.4.3 Colchicine
8.2.5 Historic and Forecasted Market Size By Disease Condition
8.2.5.1 Acute
8.2.5.2 Chronic
8.2.6 Historic and Forecasted Market Size By Distribution Channel
8.2.6.1 Hospital Pharmacies
8.2.6.2 Retail Pharmacies and Online Pharmacies
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Gout Disease Treatment Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By Type
8.3.4.1 NSAIDs
8.3.4.2 Corticosteroids
8.3.4.3 Colchicine
8.3.5 Historic and Forecasted Market Size By Disease Condition
8.3.5.1 Acute
8.3.5.2 Chronic
8.3.6 Historic and Forecasted Market Size By Distribution Channel
8.3.6.1 Hospital Pharmacies
8.3.6.2 Retail Pharmacies and Online Pharmacies
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Gout Disease Treatment Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By Type
8.4.4.1 NSAIDs
8.4.4.2 Corticosteroids
8.4.4.3 Colchicine
8.4.5 Historic and Forecasted Market Size By Disease Condition
8.4.5.1 Acute
8.4.5.2 Chronic
8.4.6 Historic and Forecasted Market Size By Distribution Channel
8.4.6.1 Hospital Pharmacies
8.4.6.2 Retail Pharmacies and Online Pharmacies
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Gout Disease Treatment Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By Type
8.5.4.1 NSAIDs
8.5.4.2 Corticosteroids
8.5.4.3 Colchicine
8.5.5 Historic and Forecasted Market Size By Disease Condition
8.5.5.1 Acute
8.5.5.2 Chronic
8.5.6 Historic and Forecasted Market Size By Distribution Channel
8.5.6.1 Hospital Pharmacies
8.5.6.2 Retail Pharmacies and Online Pharmacies
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Gout Disease Treatment Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By Type
8.6.4.1 NSAIDs
8.6.4.2 Corticosteroids
8.6.4.3 Colchicine
8.6.5 Historic and Forecasted Market Size By Disease Condition
8.6.5.1 Acute
8.6.5.2 Chronic
8.6.6 Historic and Forecasted Market Size By Distribution Channel
8.6.6.1 Hospital Pharmacies
8.6.6.2 Retail Pharmacies and Online Pharmacies
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Gout Disease Treatment Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By Type
8.7.4.1 NSAIDs
8.7.4.2 Corticosteroids
8.7.4.3 Colchicine
8.7.5 Historic and Forecasted Market Size By Disease Condition
8.7.5.1 Acute
8.7.5.2 Chronic
8.7.6 Historic and Forecasted Market Size By Distribution Channel
8.7.6.1 Hospital Pharmacies
8.7.6.2 Retail Pharmacies and Online Pharmacies
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
Global Gout Disease Treatment Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 2.58 Billion |
|
Forecast Period 2024-32 CAGR: |
8.4% |
Market Size in 2032: |
USD 5.34 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Disease Condition |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
